What causes the death of dopaminergic neurons in Parkinson's disease?

Progress in Brain Research

Volumn 183, Issue C, 2010, Pages 59-77

  Surmeier, D James ^a   Guzman, Jaime N ^a   Sanchez Padilla, Javier ^a   Goldberg, Joshua A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; LEVODOPA;

ARTICLE; CELL DEATH; CYTOPLASM; DOPAMINERGIC NERVE CELL; HUMAN; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SUBSTANTIA NIGRA;

EID: 77955354681     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(10)83004-3     Document Type: Chapter

References (128)

1. Amini B., Clark J.W., Canavier C.C. Calcium dynamics underlying pacemaker-like and burst firing oscillations in midbrain dopaminergic neurons: A computational study. Journal of Neurophysiology 1999, 82:2249-2261.
2. Andres-Mateos E., Perier C., Zhang L., Blanchard-Fillion B., Greco T.M., Thomas B., et al. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:14807-14812.
3. Andrews Z.B., Horvath B., Barnstable C.J., Elsworth J., Yang L., Beal M.F., et al. Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease. Journal of Neuroscience 2005, 25:184-191.
4. Andrews Z.B., Rivera A., Elsworth J.D., Roth R.H., Agnati L., Gago B., et al. Uncoupling protein-2 promotes nigrostriatal dopamine neuronal function. European Journal of Neuroscience 2006, 24:32-36.
5. Arbuthnott G.W., Wickens J. Space, time and dopamine. Trends in Neurosciences 2007, 30:62-69.
6. Backman L., Ginovart N., Dixon R.A., Wahlin T.B., Wahlin A., Halldin C., et al. Age-related cognitive deficits mediated by changes in the striatal dopamine system. The American Journal of Psychiatry 2000, 157:635-637.
7. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Annals of Neurology 1995, 38:357-366.
8. Beal M.F. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Annals of Neurology 1998, 44:S110-S114.
9. Bean B.P. Nitrendipine block of cardiac calcium channels: High-affinity binding to the inactivated state. Proceedings of the National Academy of Sciences of the United States of America 1984, 81:6388-6392.
10. Becker C., Jick S.S., Meier C.R. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008, 70:1438-1444.
11. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nature Genetics 2006, 38:515-517.
12. Bender A., Schwarzkopf R.M., McMillan A., Krishnan K.J., Rieder G., Neumann M., et al. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. Journal of Neurology 2008, 255:1231-1235.
13. Berridge M.J., Lipp P., Bootman M.D. The versatility and universality of calcium signalling. Nature Reviews Molecular Cell Biology 2000, 1:11-21.
14. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience 2000, 3:1301-1306.
15. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends in Molecular Medicine 2009, 15:89-100.
16. Blythe S.N., Wokosin D., Atherton J.F., Bevan M.D. Cellular mechanisms underlying burst firing in substantia nigra dopamine neurons. Journal of Neuroscience 2009, 29:15531-15541.
17. Bonci A., Grillner P., Mercuri N.B., Bernardi G. L-type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dopaminergic neurons. Journal of Neuroscience 1998, 18:6693-6703.
18. Boumezbeur F., Mason G.F., de Graaf R.A., Behar K.L., Cline G.W., Shulman G.I., et al. Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. Journal of Cerebral Blood Flow and Metabolism 2010, 30:211-221.
19. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell and Tissue Research 2004, 318:121-134.
20. Brand M.D., Affourtit C., Esteves T.C., Green K., Lambert A.J., Miwa S., et al. Mitochondrial superoxide: Production, biological effects, and activation of uncoupling proteins. Free Radical Biology & Medicine 2004, 37:755-767.
21. Burke R.E., Dauer W.T., Vonsattel J.P. A critical evaluation of the Braak staging scheme for Parkinson's disease. Annals of Neurology 2008, 64:485-491.
22. Burlhis T.M., Aghajanian G.K. Pacemaker potentials of serotonergic dorsal raphe neurons: Contribution of a low-threshold ca2+ conductance. Synapse 1987, 1:582-588.
23. Calne D.B., Langston J.W. Aetiology of Parkinson's disease. Lancet 1983, 2:1457-1459.
24. Chan C.S., Guzman J.N., Ilijic E., Mercer J.N., Rick C., Tkatch T., et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007, 447:1081-1086.
25. Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., et al. Drosophila PINK1 is required for mitochondrial function and interacts genetically with Parkin. Nature 2006, 441:1162-1166.
26. Collier T.J., Lipton J., Daley B.F., Palfi S., Chu Y., Sortwell C., et al. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: Diminished compensatory mechanisms as a prelude to Parkinsonism. Neurobiology of Disease 2007, 26:56-65.
27. Csordas G., Renken C., Varnai P., Walter L., Weaver D., Buttle K.F., et al. Structural and functional features and significance of the physical linkage between ER and mitochondria. The Journal of Cell Biology 2006, 174:915-921.
28. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122(Pt 8):1437-1448.
29. Deister C.A., Teagarden M.A., Wilson C.J., Paladini C.A. An intrinsic neuronal oscillator underlies dopaminergic neuron bursting. Journal of Neuroscience 2009, 29:15888-15897.
30. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurology 2006, 5:525-535.
31. Desireddi J.R., Farrow K.N., Marks J.D., Waypa G.B., Schumacker P.T. Hypoxia increases ROS signaling and cytosolic ca2+ in pulmonary artery smooth muscle cells of mouse lungs slices. Antioxidants & Redox Signaling 2010, 12:595-602.
32. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
33. Eisenberg M.J., Brox A., Bestawros A.N. Calcium channel blockers: An update. American Journal of Medicine 2004, 116:35-43.
34. Exner N., Treske B., Paquet D., Holmstrom K., Schiesling C., Gispert S., et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by Parkin. Journal of Neuroscience 2007, 27:12413-12418.
35. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. Journal of Neurology 2005, 252(Suppl. 4):IV37-IV42.
36. Fitton A., Benfield P. Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1990, 40:31-74.
37. Fronczek R., Overeem S., Lee S.Y., Hegeman I.M., van Pelt J., van Duinen S.G., et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007, 130:1577-1585.
38. Galvin J.E., Uryu K., Lee V.M., Trojanowski J.Q. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:13450-13455.
39. Gasser T. Mendelian forms of Parkinson's disease. Biochimica et Biophysica Acta 2009, 1792:587-596.
40. German D.C., Manaye K.F., Sonsalla P.K., Brooks B.A. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced Parkinsonism: Sparing of calbindin-D28k-containing cells. Annals of the New York Academy of Sciences 1992, 648:42-62.
41. German D.C., Manaye K.F., White C.L., Woodward D.J., McIntire D.D., Smith W.K., et al. Disease-specific patterns of locus coeruleus cell loss. Annals of Neurology 1992, 32:667-676.
42. Grace A.A., Bunney B.S. The control of firing pattern in nigral dopamine neurons: Single spike firing. Journal of Neuroscience 1984, 4:2866-2876.
43. Greenamyre J.T., Hastings T.G. Biomedicine. Parkinson's-Divergent causes, convergent mechanisms. Science 2004, 304:1120-1122.
44. Greenamyre J.T., O'Brien C.F. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Archives of Neurology 1991, 48:977-981.
45. Greene J.C., Whitworth A.J., Kuo I., Andrews L.A., Feany M.B., Pallanck L.J. Mitochondrial pathology and apoptotic muscle degeneration in drosophila Parkin mutants. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:4078-4083.
46. Guzman J.N., Sanchez-Padilla J., Chan C.S., Surmeier D.J. Robust pacemaking in substantia nigra dopaminergic neurons. Journal of Neuroscience 2009, 29:11011-11019.
47. Hajnoczky G., Davies E., Madesh M. Calcium signaling and apoptosis. Biochemical and Biophysical Research Communications 2003, 304:445-454.
48. Hanson G.T., Aggeler R., Oglesbee D., Cannon M., Capaldi R.A., Tsien R.Y., et al. Investigating mitochondrial redox potential with redox-sensitive green fluorescent protein indicators. The Journal of Biological Chemistry 2004, 279:13044-13053.
49. Harman D. The free radical theory of aging. Antioxidants & Redox Signaling 2003, 5:557-561.
50. Hartman A.S., Hunot S., Hirsch E.C. Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter. Experimental Neurology 2003, 184:561-564.
51. Hawkes C.H., Del Tredici K., Braak H. Parkinson's disease: A dual-hit hypothesis. Neuropathology and Applied Neurobiology 2007, 33:599-614.
52. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: A target for neuroprotection?. The Lancet Neurology 2009, 8:382-397.
53. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacological Reviews 1966, 18:925-964.
54. Huisman E., Uylings H.B., Hoogland P.V. Gender-related changes in increase of dopaminergic neurons in the olfactory bulb of Parkinson's disease patients. Movement Disorders 2008, 23:1407-1413.
55. Hung A.Y., Schwarzschild M.A. Clinical trials for neuroprotection in Parkinson's disease: Overcoming angst and futility?. Current Opinion in Neurology 2007, 20:477-483.
56. Hunot S., Hirsch E.C. Neuroinflammatory processes in Parkinson's disease. Annals of Neurology 2003, 53(Suppl. 3):S49-S58. discussion S58-S60.
57. Hunot S., Vila M., Teismann P., Davis R.J., Hirsch E.C., Przedborski S., et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:665-670.
58. Ishikawa T., Dhawan V., Kazumata K., Chaly T., Mandel F., Neumeyer J., et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. Journal of Nuclear Medicine 1996, 37:1760-1765.
59. Ito H., Goto S., Sakamoto S., Hirano A. Calbindin-D28k in the basal ganglia of patients with Parkinsonism. Annals of Neurology 1992, 32:543-550.
60. Jellinger K.A. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathologica 2008, 116:1-16.
61. Jellinger K.A. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochimica et Biophysica Acta 2009, 1792:730-740.
62. Kahle P.J., Waak J., Gasser T. DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radical Biology & Medicine 2009, 47:1354-1361.
63. Kamel F., Tanner C., Umbach D., Hoppin J., Alavanja M., Blair A., et al. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. American Journal of Epidemiology 2007, 165:364-374.
64. Kanaan N.M., Kordower J.H., Collier T.J. Age-related changes in dopamine transporters and accumulation of 3-nitrotyrosine in rhesus monkey midbrain dopamine neurons: Relevance in selective neuronal vulnerability to degeneration. European Journal of Neuroscience 2008, 27:3205-3215.
65. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. The New England Journal of Medicine 1988, 318:876-880.
66. Klivenyi P., Ferrante R.J., Matthews R.T., Bogdanov M.B., Klein A.M., Andreassen O.A., et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine 1999, 5:347-350.
67. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine 2008, 14:504-506.
68. Koschak A., Reimer D., Huber I., Grabner M., Glossmann H., Engel J., et al. Alpha 1d (cav1.3) subunits can form L-type ca2+ channels activating at negative voltages. The Journal of Biological Chemistry 2001, 276:22100-22106.
69. Kupsch A., Sautter J., Schwarz J., Riederer P., Gerlach M., Oertel W.H. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Research 1996, 741:185-196.
70. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
71. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine 2008, 14:501-503.
72. Li Y., Gao X.B., Sakurai T., van den Pol A.N. Hypocretin/orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. Neuron 2002, 36:1169-1181.
73. Liang C.L., Wang T.T., Luby-Phelps K., German D.C. Mitochondria mass is low in mouse substantia nigra dopamine neurons: Implications for Parkinson's disease. Experimental Neurology 2007, 203:370-380.
74. Magyar K., Szende B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 2004, 25:233-242.
75. Mannhold R. Calcium antagonists of the dihydropyridine type: Pharmaceutical chemistry and molecular pharmacology. Pharmazie in Unserer Zeit 1995, 24:137-153.
76. Matsuda W., Furuta T., Nakamura K.C., Hioki H., Fujiyama F., Arai R., et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. Journal of Neuroscience 2009, 29:444-453.
77. Matzuk M.M., Saper C.B. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Annals of Neurology 1985, 18:552-555.
78. McCormack A.L., Di Monte D.A., Delfani K., Irwin I., DeLanney L.E., Langston W.J., et al. Aging of the nigrostriatal system in the squirrel monkey. The Journal of Comparative Neurology 2004, 471:387-395.
79. Mendez I., Vinuela A., Astradsson A., Mukhida K., Hallett P., Robertson H., et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nature Medicine 2008, 14:507-509.
80. Mercuri N.B., Bonci A., Calabresi P., Stratta F., Stefani A., Bernardi G. Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. British Journal of Pharmacology 1994, 113:831-838.
81. Morikawa H., Khodakhah K., Williams J.T. Two intracellular pathways mediate metabotropic glutamate receptor-induced ca2+ mobilization in dopamine neurons. Journal of Neuroscience 2003, 23:149-157.
82. Mosharov E.V., Larsen K.E., Kanter E., Phillips K.A., Wilson K., Schmitz Y., et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009, 62:218-229.
83. Murchison D., Griffith W.H. Low-voltage activated calcium currents increase in basal forebrain neurons from aged rats. Journal of Neurophysiology 1995, 74:876-887.
84. Murchison D., Griffith W.H. Calcium buffering systems and calcium signaling in aged rat basal forebrain neurons. Aging Cell 2007, 6:297-305.
85. Nedergaard S., Flatman J.A., Engberg I. Nifedipine- and omega-conotoxin-sensitive ca2+ conductances in guinea-pig substantia nigra pars compacta neurones. Journal of Physiology (Paris) 1993, 466:727-747.
86. Nicholls D.G. Oxidative stress and energy crises in neuronal dysfunction. Annals of the New York Academy of Sciences 2008, 1147:53-60.
87. Olanow C.W., Prusiner S.B. Is Parkinson's disease a prion disorder?. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:12571-12572.
88. Orrenius S.B., Zhivotovsky B., Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nature Reviews Molecular Cell Biology 2003, 4:552-565.
89. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., et al. Mitochondrial dysfunction and oxidative damage in Parkin-deficient mice. The Journal of Biological Chemistry 2004, 279:18614-18622.
90. Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., et al. Mitochondrial dysfunction in drosophila PINK1 mutants is complemented by Parkin. Nature 2006, 441:1157-1161.
91. Pignatelli A., Ackman J.B., Vigetti D., Beltrami A.P., Zucchini S., Belluzzi O. A potential reservoir of immature dopaminergic replacement neurons in the adult mammalian olfactory bulb. Pflügers Archiv 2009, 457:899-915.
92. Pignatelli A., Kobayashi K., Okano H., Belluzzi O. Functional properties of dopaminergic neurones in the mouse olfactory bulb. Journal of Physiology (Paris) 2005, 564:501-514.
93. Ping H.X., Shepard P.D. Apamin-sensitive ca(2+)-activated K+ channels regulate pacemaker activity in nigral dopamine neurons. NeuroReport 1996, 7:809-814.
94. Pinton P., Rimessi A., Marchi S., Orsini F., Migliaccio E., Giorgio M., et al. Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66shc. Science 2007, 315:659-663.
95. Postuma R.B., Lang A.E., Massicotte-Marquez J., Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006, 66:845-851.
96. Przedborski S., Tieu K., Perier C., Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. Journal of Bioenergetics and Biomembranes 2004, 36:375-379.
97. Puopolo M., Raviola E., Bean B.P. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. Journal of Neuroscience 2007, 27:645-656.
98. Putzier I., Kullmann P.H., Horn J.P., Levitan E.S. Cav1.3 Channel voltage dependence, not ca2+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons. Journal of Neuroscience 2009, 29:15414-15419.
99. Reeve A.K., Krishnan K.J., Turnbull D.M. Age related mitochondrial degenerative disorders in humans. Biotechnology Journal 2008, 3:750-756.
100. Riederer P., Wuketich S. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. Journal of Neural Transmission 1976, 38:277-301.
101. Ritz B., Qian L., Rhodes S.L., Schernhammer E., Olsen J., Friis S. L-type calcium channel blockers and Parkinson's disease in Denmark. Annals of Neurology 2010, 67(5):600-606.
102. Rizzuto R. Intracellular Ca(2+) pools in neuronal signalling. Current Opinion in Neurobiology 2001, 11:306-311.
103. Rizzuto R., Pozzan T. Microdomains of intracellular ca2+: Molecular determinants and functional consequences. Physiological Reviews 2006, 86:369-408.
104. Romo R., Schultz W. Dopamine neurons of the monkey midbrain: Contingencies of responses to active touch during self-initiated arm movements. Journal of Neurophysiology 1990, 63:592-606.
105. Saper C.B., Sorrentino D.M., German D.C., de Lacalle S. Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease. Annals of Neurology 1991, 29:577-584.
106. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurology 2008, 7:97-109.
107. Shults C.W. Therapeutic role of coenzyme Q(10) in Parkinson's disease. Pharmacology & Therapeutics 2005, 107:120-130.
108. Schultz W. Multiple dopamine functions at different time courses. Annual Review of Neuroscience 2007, 30:259-288.
109. Sinnegger-Brauns M.J., Huber I.G., Koschak A., Wild C., Obermair G.J., Einzinger U., et al. Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Molecular Pharmacology 2009, 75:407-414.
110. Sonsalla P.K., Albers D.S., Zeevalk G.D. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of Parkinsonism. Amino Acids 1998, 14:69-74.
111. Stark A.K., Pakkenberg B. Histological changes of the dopaminergic nigrostriatal system in aging. Cell and Tissue Research 2004, 318:81-92.
112. Stevens D.R., Haas H.L. Calcium-dependent prepotentials contribute to spontaneous activity in rat tuberomammillary neurons. Journal of Physiology (Paris) 1996, 493(Pt 3):747-754.
113. Striessnig J., Koschak A., Sinnegger-Brauns M.J., Hetzenauer A., Nguyen N.K., Busquet P., et al. Role of voltage-gated L-type ca2+ channel isoforms for brain function. Biochemical Society Transactions 2006, 34:903-909.
114. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends in Neurosciences 2007, 30:244-250.
115. Taddese A., Bean B.P. Subthreshold sodium current from rapidly inactivating sodium channels drives spontaneous firing of tuberomammillary neurons. Neuron 2002, 33:587-600.
116. Takakusaki K., Kitai S.T. Ionic mechanisms involved in the spontaneous firing of tegmental pedunculopontine nucleus neurons of the rat. Neuroscience 1997, 78:771-794.
117. Tanner C.M., Ross G.W., Jewell S.A., Hauser R.A., Jankovic J., Factor S.A., et al. Occupation and risk of Parkinsonism: A multicenter case-control study. Archives of Neurology 2009, 66:1106-1113.
118. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiology Disease 2010, 37:510-518.
119. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:5473-5478.
120. Tepper J.M., Sawyer S.F., Groves P.M. Electrophysiologically identified nigral dopaminergic neurons intracellularly labeled with HRP: Light-microscopic analysis. Journal of Neuroscience 1987, 7:2794-2806.
121. Thannickal T.C., Lai Y.Y., Siegel J.M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007, 130:1586-1595.
122. Travagli R.A., Gillis R.A. Hyperpolarization-activated currents, IH and IKIR, in rat dorsal motor nucleus of the vagus neurons in vitro. Journal of Neurophysiology 1994, 71:1308-1317.
123. Wallace D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annual Review of Genetics 2005, 39:359-407.
124. Wang W., Fang H., Groom L., Cheng A., Zhang W., Liu J., et al. Superoxide flashes in single mitochondria. Cell 2008, 134:279-290.
125. Williams J.T., North R.A., Shefner S.A., Nishi S., Egan T.M. Membrane properties of rat locus coeruleus neurones. Neuroscience 1984, 13:137-156.
126. Wilson C.J., Callaway J.C. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. Journal of Neurophysiology 2000, 83:3084-3100.
127. Yamanaka A., Beuckmann C.T., Willie J.T., Hara J., Tsujino N., Mieda M., et al. Hypothalamic orexin neurons regulate arousal According To energy balance in mice. Neuron 2003, 38:701-713.
128. Zweifel L.S., Parker J.G., Lobb C.J., Rainwater A., Wall V.Z., Fadok J.P., et al. Disruption of NMDAR-dependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:7281-7288.